Blog, News, Companies, blood glucose meters, oral, Nasal, transdermal, insulin,type 2, pancreatic islet cells, Macular Edema, Ulcers, continuous glucose monitoring, HbA1c, hemoglobin A1C, oral anti-diabetic agent, data management system, Hypoglycemia, glucagon, therapeutic vaccine, peripheral neuropathy, Neuropathic pain, diabetes mellitus, type 1, foot ulcers, test strip, glycemic control, nephropathy, resistant, sensitizers, foot infections, sensor, retinopathy, non-invasive monitor...
Nov. 14, 2007--Cardium Therapeutics (AMEX:CXM) and its subsidiary, Tissue Repair Company (TRC) announced the start of recruitment for its Phase 2b clinical trial (MATRIX) to evaluate the safety and efficacy of Excellarate(TM) for the potential treatment of non-healing diabetic foot ulcers. Excellarate is a DNA-based topical gel that is being developed to be administered once or twice to stimulate wound healing... Cardium's Press Release -
